



TFW

Atty. Dkt. No. 029318-0107

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bosch et al.
Title: STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE
AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
Appl. No.: 10/035,324
Filing Date: 01/04/2002
Examiner: Mina Haghighatian
Art Unit: 1616

STATEMENT OF SUBSTANCE OF INTERVIEW

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance to 37 C.F.R. § 1.133, submitted herewith is a record of the substance of the interview on February 21, 2006, between Examiner Mina Haghighatian, regarding the above-captioned application. This statement is being submitted within one (1) month of the mailing date of March 14, 2006, of the Interview Summary and is therefore a timely response.

REMARKS

Applicant wishes to thank Examiner Haghghatian and her supervisor, Examiner Padmanabhan for the courtesies extended by them during a February 21st telephonic interview.

The claims as amended in Applicant's response filed on February 28, 2006 reflect the substance of the claim amendments discussed during the interview. Applicant and Applicant's representatives set forth reasons as to why sterile filtered nanoparticulate compositions as presently claimed are distinct from nanoparticulate compositions that are not sterile filtered. Applicant and Applicant's representatives also asserted that it was surprisingly discovered that nanoparticulate beclomethasone or budesonide particles having tyloxapol as a surface modifier can be prepared at a very small particle size allowing for sterile filtering.

Respectfully submitted,

Date March 28, 2006

FOLEY & LARDNER LLP
Customer Number: 31049
Telephone: (202) 672-5538
Facsimile: (202) 672-5399

By 

Michele M. Simkin
Attorney for Applicant
Registration No. 34,717